CheckMate -9LA Clinical Trial Data Active! Odivo (Navuriu monoantigen) combined with Ipitaph mono-resistance and limited course of chemotherapy significantly improves the total survival of first-line metastatic non-small cell lung cancer patients

On May 13, 2020, Shiguibao of Boxei announced the results of the first report of The Phase III clinical study CheckMate-9LAThe results showed that Odiwo combined with epibusandoandandand and two-cycle synchronous chemotherapy for first-line treatment in patients with metastatic non-small cell lung cancer (NSCLC) could bring statistically significant and clinical benefits to their survivalThe study reached the end of the major and critical secondary studyCompared to single-use chemotherapy, dual immunocombined chemotherapy improved the total survival (OS), non-progressive survival (PFS) and objective remission rate (ORR) in patientsa pre-set analysis of the main study endpoint total lifetime (OS) showed that at least 8.1 months of follow-up, Odivo combined with epimacoandandandand and two cycles of chemotherapy reduced the risk of death in patients by 31% compared to single-cycle chemotherapyIn addition, during a longer follow-up period (minimum 12.7 months), this combination of treatments can provide a sustained OS benefit to patients compared to single chemotherapy (median OS: 15.6 months vs 10.9 months, HR 0.66, 95% CI: 0.55-0.80)In the critical patient subgroup, all efficacy assessments showed clinical benefits regardless of the patient's PD-L1 expression level and tumor histology type (squamous or non-squamous cancer)Odivo (360mg, every 3 weeks) and Epibus monoantigen (1 mg/kg, every 6 weeks) combined with two cycles of chemotherapy are consistent with immunotherapy and chemotherapy for first-line NSCLC treatmentThese results (summary s.9501) will be presented in an oral presentation at the 2020 American Society of Clinical Oncology (ASCO) Online Annual Meeting"The results confirm that Navuriu's monoantigen combination of ipitaph monoantigen treatment for non-small cell lung cancer can extend the patient's survival, and that the addition of limited course of chemotherapy is likely to reduce the risk of early progression of the disease," said DrMartin Reck, a researcher at CheckMate 9LA and a researcher in the Chest Oncology Department of the Grosshansdorf Lung Research Center in GermanyThe CheckMate 9LA results confirm edifying the survival benefits of two cycles of synchronous chemotherapy for patients, and in all key patient subgroups, we observed survival benefits early in the subgroup, and the benefits continued during the year of follow-upAs the data matures, I think the survival benefits will be expected to improve furtherat least 12.7 months after follow-up, Odivo's combined Ipitano and limited course of chemotherapy improved the patient's OS, regardless of the patient's PD-L1 expression levelIn 1% of pD-L1 patients, the risk of death was reduced by 38% (HR 0.62, 95% CI: 0.45-0.85), and in patients with PD-L1 to 1% the risk of death decreased by 36% (HR 0.64, 95% CI: 0.50 to 0.82)In addition, the one-year PFS rate was 33% in patients using double immunotherapy, compared with 18% in patients with monotherapy (HR 0.68, 95% CI: 0.57-0.82) The ORR was 38% in patients in the double immunotherapy group and 25% in patients with chemotherapy alone Dr Nick Botwood, Vice President of Clinical Development of Oncology at , said: "The situation for patients with metastatic non-small cell lung cancer varies, and in the face of a large patient population, we are developing and developing a wide range of potentially durable treatment options to provide patients with new treatment options The published CheckMate 9LA Annual Lifetime Data and CheckMate 227 3-Year Follow-up Data further confirm the clinical value of Odivo's combined Ipitaph monoantigen in the first-line treatment of non-small cell lung cancer, the first dual-immune treatment in the field Odivo is a unique combination of two immunocheckpoint inhibitors with potential synergies for two different checkpoints (PD-1 and CTLA-4) to help eliminate tumor cells: Epiwood monoresist helps activate and multiply T cells, while Odivo helps existing T-cells detect tumors Some T-cells activated by Epima can differentiate into memory T-cells, which is expected to achieve a long-term immune response Based on the combination of Odivo and Epima monoantigen therapy, the addition of limited courses of chemotherapy can help patients achieve early disease control Note: Ipitano not yet listed in China
source: MedSci